How are energy investors positioned?
SAN DIEGO - Dexcom, Inc. (DXCM), a $34.89 billion market cap leader in glucose monitoring technology, announced Monday the release of a new AI-powered photo meal logging feature for its Stelo over-the-counter glucose biosensor, following the feature’s earlier introduction on the company’s Dexcom G7 device. According to InvestingPro data, the company maintains a "GREAT" financial health score, reflecting its strong market position in healthcare technology innovation.
The Smart Food Logging feature allows users to take photos of their meals directly in the Stelo or Dexcom G7 app, where artificial intelligence automatically identifies ingredients and populates meal descriptions. According to the company’s press release, Dexcom G7 is currently the only prescription continuous glucose monitor in the U.S. that supports photo logging. This innovation comes as Dexcom demonstrates solid growth, with revenue increasing by 9.11% in the last twelve months.
"Diet plays a crucial role in managing glucose levels, and our new Smart Food Logging feature removes barriers to food tracking, making it easier to consistently log and understand the impact of meals," said Jake Leach, president and chief operating officer at Dexcom.
The feature joins other recent enhancements to Dexcom’s products, including Weekly Insights in Stelo, which offers personalized recommendations related to diet, exercise, and sleep; integration with Oura to provide a combined view of glucose data and other health metrics; customizable target ranges in Dexcom G7; and a Glucose Impact feature that shows how logged events affect glucose levels.
Stelo, which received FDA clearance as an over-the-counter glucose biosensor, and Dexcom G7 users can access the new Smart Food Logging feature by updating to the latest version of the app on iOS and Android platforms. With strong analyst support and trading near its 52-week high, Dexcom continues to demonstrate market leadership. For detailed analysis and additional insights, including 12 more exclusive ProTips, visit InvestingPro.
Dexcom, founded in 1999, describes itself as a developer of glucose biosensing technology. The information in this article is based on a company press release.
In other recent news, Dexcom, Inc. has initiated a recall of certain glucose monitoring receivers due to a speaker malfunction that could prevent alerts for dangerous blood sugar levels. The recall affects the Dexcom G6, G7, ONE, and ONE+ receivers, and the FDA has classified it as the most serious type of recall. In the realm of analyst activities, Truist Securities initiated coverage on Dexcom with a Buy rating and a $102.00 price target, highlighting the company’s leading role in the continuous glucose monitoring market. Piper Sandler reiterated its Overweight rating with a $100.00 price target, noting strong adoption of continuous glucose monitoring among basal insulin users.
Goldman Sachs also initiated coverage of Dexcom, assigning a Buy rating and setting a 12-month price target of $104.00, citing the company’s innovative technology and growth potential. Meanwhile, RBC Capital Markets maintained an Outperform rating with a $100.00 price target, following a Non-Deal Roadshow. The firm emphasized that Dexcom’s growth opportunities may be undervalued by the market and suggested the company could exceed its 2025 financial targets. These developments reflect a mix of product challenges and optimistic analyst outlooks for Dexcom’s future in the medical device industry.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.